Immunochem

Immunochem leverages a proprietary AI-powered platform, EVOBodies™, to design and validate single-domain antibodies (VHH) and minibinders, bypassing traditional, unpredictable immunization methods. The company positions itself as a service provider to bio-pharmaceutical R&D teams, offering a rapid, 6-week timeline to generate precise binding tools against difficult targets, including toxic or non-immunogenic antigens. By combining computational design with wet-lab validation, Immunochem aims to address key industry pain points of reproducibility, time, and uncertainty in early-stage research and diagnostic reagent development. Its value proposition centers on streamlining processes and providing reliable starting materials for critical projects.

EVOBodies™ platform combining AI/computational design with recombinant biology to generate single-domain antibodies (VHH) and de novo minibinders against challenging antigens, without animal immunization.

Immunochem competes in the AI-driven protein design space against well-funded startups (e.g., Absci, Generate Biomedicines) and internal biopharma efforts. Its specific niche is the rapid, service-based generation of validated VHH/minibinders. It also competes indirectly with traditional antibody suppliers and CROs offering animal-based discovery, against which it emphasizes speed, predictability, and access to difficult targets.